{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:23:24Z","timestamp":1791228204352,"version":"4.1.0"},"reference-count":147,"publisher":"Rambam Health Corporation","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rambam Maimonides Med J"],"abstract":"<jats:p>Rheumatoid diseases, including rheumatoid arthritis, osteoarthritis, and fibromyalgia, are characterized by progressive inflammation in the musculoskeletal system, predominantly affecting the joints and leading to cartilage and bone damage. The resulting pain and ongoing degradation of the musculoskeletal system contribute to reduced physical activity, ultimately impacting quality of life and imposing a substantial socioeconomic burden. Unfortunately, current therapeutics have limited efficacy in slowing disease progression and managing pain. Thus, the development of novel and alternative therapies is imperative. Cannabinoids possess beneficial properties as potential treatments for rheumatoid diseases due to their anti-inflammatory and analgesic properties. Preclinical studies have demonstrated promising results in halting disease progression and relieving pain. However, there is a scarcity of patient clinical studies, and the available data show mixed results. Consequently, there are currently no established clinical recommendations regarding the utilization of cannabis for treating rheumatoid diseases. In this review, we aim to explore the concept of cannabis use for rheumatoid diseases, including potential adverse effects. We will provide an overview of the data obtained from preclinical and clinical trials and from retrospective studies on the efficacy and safety of cannabis in the treatment of rheumatoid diseases.<\/jats:p>","DOI":"10.5041\/rmmj.10509","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T09:29:56Z","timestamp":1698658196000},"page":"e0022","source":"Crossref","is-referenced-by-count":18,"title":["Cannabis and Rheumatoid Arthritis: A Scoping Review Evaluating the Benefits, Risks, and Future Research Directions"],"prefix":"10.5041","volume":"14","author":[{"name":"Medical Cannabis Research and Innovation Center, Rambam Health Care Campus, Haifa, Israel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Paland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haya","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Medical Cannabis Research and Innovation Center, Rambam Health Care Campus, Haifa, Israel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Pechkovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Medical Cannabis Research and Innovation Center, Rambam Health Care Campus, Haifa, Israel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miran","family":"Aswad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Medical Cannabis Research and Innovation Center, Rambam Health Care Campus, Haifa, Israel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayana","family":"Shagidov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Medical Cannabis Research and Innovation Center, Rambam Health Care Campus, Haifa, Israel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igal","family":"Louria-Hayon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Medical Cannabis Research and Innovation Center, Rambam Health Care Campus, Haifa, Israel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Clinical Research Institute at Rambam (CRIR), Rambam Health Care Campus, Haifa, Israel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2983","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","unstructured":"1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388:2023-38.","journal-title":"Lancet"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.autrev.2017.09.013","article-title":"Imaging aspects of interstitial lung disease in patients with rheumatoid arthritis: literature review","volume":"17","author":"Balbir-Gurman","year":"2018","unstructured":"2. Balbir-Gurman A, Guralnik L, Yigla M, Braun-Moscovici Y, Hardak E. Imaging aspects of interstitial lung disease in patients with rheumatoid arthritis: literature review. Autoimmun Rev 2018;17:87-93.","journal-title":"Autoimmun Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","article-title":"The global burden of rheumatoid arthritis: estimates from the Global Bur\u00acden of Disease 2010 study","volume":"73","author":"Cross","year":"2014","unstructured":"3. Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the Global Bur\u00acden of Disease 2010 study. Ann Rheum Dis 2014;73: 1316-22.","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s10067-020-05438-0","article-title":"Chronological effects of non-steroidal anti-inflammatory drug ther\u00acapy on oxidative stress and antioxidant status in patients with rheumatoid arthritis","volume":"40","author":"Nawaz","year":"2021","unstructured":"4. Nawaz H, Ali A, Rehman T, Aslam A. Chronological effects of non-steroidal anti-inflammatory drug ther\u00acapy on oxidative stress and antioxidant status in patients with rheumatoid arthritis. Clin Rheumatol 2021;40:1767-78.","journal-title":"Clin Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","unstructured":"5. Smolen JS, Landew\u00e9 R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","unstructured":"6. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:1-25.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJM199507203330302","article-title":"The effect of gluco\u00accorticoids on joint destruction in rheumatoid arthri\u00actis","volume":"333","author":"Kirwan","year":"1995","unstructured":"7. Kirwan JR; Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of gluco\u00accorticoids on joint destruction in rheumatoid arthri\u00actis. N Engl J Med 1995;333:142-6.","journal-title":"N Engl J Med"},{"key":"ref7","unstructured":"8. Yasir M, Goyal A, Sonthalia S. Corticosteroid Adverse Effects. 2023 Jul 3. In: StatPearls [Internet]. Trea\u00acsure Island, FL: StatPearls Publishing; 2023 Jan. PMID: 30285357. Available at: https:\/\/www.ncbi. nlm.nih.gov\/books\/NBK531462\/ (accessed October 5, 2023)."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/17425255.2020.1777279","article-title":"Using phar-macogenetics to predict methotrexate response in rheumatoid arthritis patients","volume":"16","author":"Szostak","year":"2020","unstructured":"9. Szostak B, Machaj F, Rosik J, Pawlik A. Using phar-macogenetics to predict methotrexate response in rheumatoid arthritis patients. Expert Opin Drug Metab Toxicol 2020;16:617-26.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic lit-erature review informing the 2013 update of the EULAR recommendations for management of rheu\u00acmatoid arthritis","volume":"73","author":"Ramiro","year":"2014","unstructured":"10. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic lit-erature review informing the 2013 update of the EULAR recommendations for management of rheu\u00acmatoid arthritis. Ann Rheum Dis 2014;73:529-35.","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Baron EP. Comprehensive review of medicinal mari-juana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it's been... Headache 2015;55:885-916.","DOI":"10.1111\/head.12570"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Gould J. The cannabis crop. Nature 2015;525:S2-3.","DOI":"10.1038\/525S2a"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fpls.2016.00019","article-title":"Cannabis sativa: the plant of the thousand and one molecules","volume":"7","author":"Andre","year":"2016","unstructured":"13. Andre CM, Hausman JF, Guerriero G. Cannabis sativa: the plant of the thousand and one molecules. Front Plant Sci 2016;7:19.","journal-title":"Front Plant Sci"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 2008;Suppl 1:10-14.","DOI":"10.1111\/j.1365-2826.2008.01671.x"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Smith TH, Sim-Selley LJ, Selley DE. Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol 2010;160:454-66.","DOI":"10.1111\/j.1476-5381.2010.00777.x"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3389\/fimmu.2021.631233","article-title":"The immu-nopathology of COVID-19 and the cannabis para-digm","volume":"12","author":"Paland","year":"2021","unstructured":"16. Paland N, Pechkovsky A, Aswad M, et al. The immu-nopathology of COVID-19 and the cannabis para-digm. Front Immunol 2021;12:327.","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature08144","article-title":"The structure and function of G-protein-coupled recep\u00actors","volume":"459","author":"Rosenbaum","year":"2009","unstructured":"17. Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G-protein-coupled recep\u00actors. Nature 2009;459:356-63.","journal-title":"Nature"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Marsicano G, Kuner R. Anatomical Distribution of Receptors, Ligands and Enzymes in the Brain and in the Spinal Cord: Circuitries and Neurochemistry. In: K\u00f6falvi A, ed. Cannabinoids and the Brain. New York, NY: Springer; 2008:161-201.","DOI":"10.1007\/978-0-387-74349-3_10"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1073\/pnas.96.10.5780","article-title":"Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice","volume":"96","author":"Zimmer","year":"1999","unstructured":"19. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 1999;96:5780-5.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00213-017-4537-5","article-title":"Regulation of cannabinoid CB2 receptor constitutive activity in vivo: repeated treatments with inverse ago\u00acnists reverse the acute activation of JNK and associ\u00acated apoptotic signaling in mouse brain","volume":"234","author":"Salort","year":"2017","unstructured":"20. Salort G, \u00c1lvaro-Bartolom\u00e9 M, Garc\u00eda-Sevilla JA. Regulation of cannabinoid CB2 receptor constitutive activity in vivo: repeated treatments with inverse ago\u00acnists reverse the acute activation of JNK and associ\u00acated apoptotic signaling in mouse brain. Psychophar\u00acmacology (Berl) 2017;234:925-41.","journal-title":"Psychophar\u00acmacology (Berl)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","unstructured":"21. Palazuelos J, Aguado T, Pazos MR, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009;132: 3152-64.","journal-title":"Brain"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0009-3084(00)00195-X","article-title":"Cannabinoid receptors and the regu-lation of immune response","volume":"108","author":"Berdyshev","year":"2000","unstructured":"22. Berdyshev EV. Cannabinoid receptors and the regu-lation of immune response. Chem Phys Lipids 2000; 108:169-90.","journal-title":"Chem Phys Lipids"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1021\/jm050709m","article-title":"New cannabidiol derivatives: synthesis, binding to canna\u00acbinoid receptor, and evaluation of their anti\u00acinflammatory activity","volume":"49","author":"Ben-Shabat","year":"2006","unstructured":"23. Ben-Shabat S, Hanu\u0161 LO, Katzavian G, Gallily R. New cannabidiol derivatives: synthesis, binding to canna\u00acbinoid receptor, and evaluation of their anti\u00acinflammatory activity. J Med Chem 2006;49:1113-17.","journal-title":"J Med Chem"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"875546","DOI":"10.3389\/fimmu.2022.875546","article-title":"High-CBD extract (CBD-X) downregulates cytokine storm systemically and locally in inflamed lungs","volume":"13","author":"Aswad","year":"2022","unstructured":"24. Aswad M, Hamza H, Pechkovsky A, et al. High-CBD extract (CBD-X) downregulates cytokine storm systemically and locally in inflamed lungs. Front Immunol 2022;13:875546.","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"6461","DOI":"10.4049\/jimmunol.164.12.6461","article-title":"9-Tetrahydrocannabinol treatment suppresses immuni\u00acty and early IFN-, IL-12, and IL-12 receptor 2 re\u00acsponses to Legionella pneumophila infection 1","volume":"164","author":"Klein","year":"2000","unstructured":"25. Klein TW, Newton CA, Nakachi N, Friedman H. 9-Tetrahydrocannabinol treatment suppresses immuni\u00acty and early IFN-, IL-12, and IL-12 receptor 2 re\u00acsponses to Legionella pneumophila infection 1. J Immunol 2000;164:6461-6.","journal-title":"J Immunol"},{"key":"ref25","unstructured":"26. Jeon YJ, Yang KH, Pulaski JT, Kaminski NE. Attenu-ation of inducible nitric oxide synthase gene expres\u00acsion by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B\/Rel activation. Mol Pharmacol 1996;50:334-41. PMID: 8700141"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.3390\/ijms20071673","article-title":"Future aspects for cannabinoids in breast cancer therapy","volume":"20","author":"Kiskov\u00e1","year":"2019","unstructured":"27. Kiskov\u00e1 T, Mungenast F, Suv\u00e1kov\u00e1 M, J\u00e4ger W, Thal-hammer T. Future aspects for cannabinoids in breast cancer therapy. Int J Mol Sci 2019;20:1673.","journal-title":"Int J Mol Sci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1074\/jbc.M109.069294","article-title":"Cannabinoids \u03949-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysac\u00accharide-activated NF-\u03baappaB and interferon-\u03b2\/STAT proinflammatory pathways in BV-2 microglial cells","volume":"285","author":"Kozela","year":"2010","unstructured":"28. Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z. Cannabinoids \u03949-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysac\u00accharide-activated NF-\u03baappaB and interferon-\u03b2\/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem 2010;285:1616-26.","journal-title":"J Biol Chem"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Juknat A, Gao F, Coppola G, Vogel Z, Kozela E. miRNA expression profiles and molecular networks in resting and LPS-activated BV-2 microglia-effect of cannabi\u00acnoids. PLoS One 2019;14:e0212039.","DOI":"10.1371\/journal.pone.0212039"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1211\/jpp.58.3.0009","article-title":"Arth\u00acritis and cannabinoids: HU-210 and Win-55,212-2 prevent IL-1 \u03b1-induced matrix degradation in bovine articular chondrocytes in-vitro","volume":"58","author":"Mbvundula","year":"2010","unstructured":"30. Mbvundula EC, Bunning RAD, Rainsford KD. Arth\u00acritis and cannabinoids: HU-210 and Win-55,212-2 prevent IL-1 \u03b1-induced matrix degradation in bovine articular chondrocytes in-vitro. J Pharm Pharmacol 2010;58:351-8.","journal-title":"J Pharm Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.bcp.2004.11.018","article-title":"Effects of cannabinoids on nitric oxide production by chon-drocytes and proteoglycan degradation in cartilage","volume":"69","author":"Mbvundula","year":"2005","unstructured":"31. Mbvundula EC, Bunning RAD, Rainsford KD. Effects of cannabinoids on nitric oxide production by chon-drocytes and proteoglycan degradation in cartilage. Biochem Pharmacol 2005;69:635-40.","journal-title":"Biochem Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/1529-0131(199801)41:1<163::AID-ART20>3.0.CO;2-9","article-title":"Dimethylheptyl-THC-11 OIC acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure","volume":"41","author":"Zurier","year":"1998","unstructured":"32. Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunt\u00acer SA, Burstein SH. Dimethylheptyl-THC-11 OIC acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum 1998;41:163-70.","journal-title":"Arthritis Rheum"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"113693","DOI":"10.1016\/j.bcp.2019.113693","article-title":"Tetrahydrocannabinolic acid A (THCA-A) reduces adiposity and prevents metabolic disease caused by diet-induced obesity","volume":"171","author":"Palomares","year":"2020","unstructured":"33. Palomares B, Ruiz-Pino F, Garrido-Rodriguez M, et al. Tetrahydrocannabinolic acid A (THCA-A) reduces adiposity and prevents metabolic disease caused by diet-induced obesity. Biochem Pharmacol 2020;171: 113693.","journal-title":"Biochem Pharmacol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0091-3057(97)00583-2","article-title":"Character-ization of \u03949-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats","volume":"60","author":"Smith","year":"1998","unstructured":"34. Smith FL, Fujimori K, Lowe J, Welch SP. Character-ization of \u03949-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav 1998;60:183-91.","journal-title":"Pharmacol Biochem Behav"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"9561","DOI":"10.1073\/pnas.160105897","article-title":"The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis","volume":"97","author":"Malfait","year":"2000","unstructured":"35. Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 2000;97: 9561-6.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejphar.2007.05.024","article-title":"The antinociceptive effect of \u03949-tetrahydrocannabinol in the arthritic rat involves the CB2 cannabinoid receptor","volume":"570","author":"Cox","year":"2007","unstructured":"36. Cox ML, Haller VL, Welch SP. The antinociceptive effect of \u03949-tetrahydrocannabinol in the arthritic rat involves the CB2 cannabinoid receptor. Eur J Phar\u00acmacol 2007;570:50-6.","journal-title":"Eur J Phar\u00acmacol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/art.20050","article-title":"A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis","volume":"50","author":"Sumariwalla","year":"2004","unstructured":"37. Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 2004;50:985-98.","journal-title":"Arthritis Rheum"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejp.818","article-title":"Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis","volume":"20","author":"Hammell","year":"2016","unstructured":"38. Hammell DC, Zhang LP, Ma F, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain 2016;20:936-48.","journal-title":"Eur J Pain"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39. Richardson D, Pearson RG, Kurian N, et al. Charac-terisation of the cannabinoid receptor system in sy\u00acnovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 2008; 10:R43.","DOI":"10.1186\/ar2401"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"IB","year":"2007","unstructured":"40. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7: 429-42.","journal-title":"Nat Rev Immunol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/ar2304","article-title":"Proteinases in the joint: clinical relevance of proteinases in joint destruction","volume":"9","author":"Rengel","year":"2007","unstructured":"41. Rengel Y, Ospelt C, Gay S. Proteinases in the joint: clinical relevance of proteinases in joint destruction. Arthritis Res Ther 2007;9:221.","journal-title":"Arthritis Res Ther"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/jcb.21046","article-title":"Suppression of fibroblast metalloprotein\u00acases by ajulemic acid, a nonpsychoactive cannabinoid acid","volume":"100","author":"Johnson","year":"2007","unstructured":"42. Johnson DR, Stebulis JA, Rossetti RG, Burstein SH, Zurier RB. Suppression of fibroblast metalloprotein\u00acases by ajulemic acid, a nonpsychoactive cannabinoid acid. J Cell Biochem 2007;100:184-90.","journal-title":"J Cell Biochem"},{"key":"ref42","unstructured":"43. Selvi E, Lorenzini S, Garcia-Gonzalez E, et al. Inhibi-tory effect of synthetic cannabinoids on cyto\u00ackine pro\u00acduction in rheumatoid fibroblast-like synoviocytes. Clin Exp Rheumatol 2008;26:574-81. PMID: 18799087."},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44. Lowin T, Pongratz G, Straub RH. The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targets. J Inflamm (Lond) 2016:13:15.","DOI":"10.1186\/s12950-016-0114-7"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41419-020-02892-1","article-title":"Cannabidiol (CBD): a killer for in-flammatory rheumatoid arthritis synovial fibroblasts","volume":"11","author":"Lowin","year":"2020","unstructured":"45. Lowin T, Tingting R, Zurmahr J, Classen T, Schneider M, Pongratz G. Cannabidiol (CBD): a killer for in-flammatory rheumatoid arthritis synovial fibroblasts. Cell Death Dis 2020;11:714.","journal-title":"Cell Death Dis"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1097\/j.pain.0000000000001896","article-title":"A random\u00acized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain","volume":"161","author":"Verrico","year":"2020","unstructured":"46. Verrico CD, Wesson S, Konduri V, et al. A random\u00acized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain 2020;161:2191-202.","journal-title":"Pain"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41423-020-0437-4","article-title":"Cannabi-noids drive Th17 cell differentiation in patients with rheumatic autoimmune diseases","volume":"18","author":"Kotschenreuther","year":"2021","unstructured":"47. Kotschenreuther K, Waqu\u00e9 I, Yan S, et al. Cannabi-noids drive Th17 cell differentiation in patients with rheumatic autoimmune diseases. Cell Mol Immunol 2021;18:764-6.","journal-title":"Cell Mol Immunol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1365-2044.2004.03674.x","article-title":"Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 \"N of 1\" studies","volume":"59","author":"Notcutt","year":"2004","unstructured":"48. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 \"N of 1\" studies. Anaesthesia 2004; 59:440-52.","journal-title":"Anaesthesia"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/kei183","article-title":"Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis","volume":"45","author":"Blake","year":"2006","unstructured":"49. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006;45:50-2.","journal-title":"Rheumatology (Oxford)"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jpain.2012.10.009","article-title":"Low-dose vaporized cannabis significan\u00acly improves neuropathic pain","volume":"14","author":"Wilsey","year":"2013","unstructured":"50. Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significan\u00acly improves neuropathic pain. J Pain 2013;14:136-48.","journal-title":"J Pain"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/j.pain.0000000000001464","article-title":"An experimental random\u00acized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibro\u00acmyalgia","volume":"160","author":"Van De Donk","year":"2019","unstructured":"51. Van De Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, Van Velzen M. An experimental random\u00acized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibro\u00acmyalgia. Pain 2019;160:860-9.","journal-title":"Pain"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"344","DOI":"10.14740\/jocmr4210","article-title":"A scoping review on clinical trials of pain reduction with cannabis administration in adults","volume":"12","author":"Haleem","year":"2020","unstructured":"52. Haleem R, Wright R. A scoping review on clinical trials of pain reduction with cannabis administration in adults. J Clin Med Res 2020;12:344-51.","journal-title":"J Clin Med Res"},{"key":"ref52","unstructured":"53. Van den Berg M, John M, Black M, et al. Cannabis-based medicinal products in arthritis, a painful conun\u00acdrum. N Z Med J 2020;133:35-45. PMID: 32438375"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"54. Weizman L, Dayan L, Brill S, et al. Cannabis analge\u00acsia in chronic neuropathic pain is associated with altered brain connectivity. Neurology 2018;91:e1285-94.","DOI":"10.1212\/WNL.0000000000006293"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1097\/j.pain.0000000000000706","article-title":"Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis","volume":"157","author":"Ste-Marie","year":"2016","unstructured":"55. Ste-Marie PA, Shir Y, Rampakakis E, et al. Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis. Pain 2016;157:2792-7.","journal-title":"Pain"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ejp.1118","article-title":"Efficacy, tolera-bility and safety of cannabis-based medicines for chronic pain management - an overview of syste-matic reviews","volume":"22","author":"H\u00e4user","year":"2018","unstructured":"56. H\u00e4user W, Petzke F, Fitzcharles MA. Efficacy, tolera-bility and safety of cannabis-based medicines for chronic pain management - an overview of syste-matic reviews. Eur J Pain 2018;22:455-70.","journal-title":"Eur J Pain"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"57. Jennings JM, Williams MA, Levy DL, Johnson RM, Eschen CL, Dennis DA. Has self-reported marijuana use changed in patients undergoing total joint arthro\u00acplasty after the legalization of marijuana? Clin Orthop Relat Res 2019;477:95-100.","DOI":"10.1097\/CORR.0000000000000339"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1742-1241.2004.00271.x","article-title":"The medicinal use of cannabis in the UK: results of a nationwide survey","volume":"59","author":"Ware","year":"2005","unstructured":"58. Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract 2005;59:291-5.","journal-title":"Int J Clin Pract"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/rheumatology\/keaa534","article-title":"Cannabis use assessment and its impact on pain in rheumatologic diseases: a systematic re\u00acview and meta-analysis","volume":"60","author":"Guillouard","year":"2021","unstructured":"59. Guillouard M, Authier N, Pereira B, Soubrier M, Mathieu S. Cannabis use assessment and its impact on pain in rheumatologic diseases: a systematic re\u00acview and meta-analysis. Rheumatology (Oxford) 2021;60:549-56.","journal-title":"Rheumatology (Oxford)"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/acr2.11138","article-title":"Medical cannabis use by rheumatology patients fol\u00aclowing recreational legalization: a prospective obser\u00acvational study of 1000 patients in Canada","volume":"2","author":"Fitzcharles","year":"2020","unstructured":"60. Fitzcharles MA, Rampakakis E, Sampalis J, et al. Medical cannabis use by rheumatology patients fol\u00aclowing recreational legalization: a prospective obser\u00acvational study of 1000 patients in Canada. ACR Open Rheumatol 2020;2:286-93.","journal-title":"ACR Open Rheumatol"},{"key":"ref60","unstructured":"61. Urits I, Charipova K, Gress K, et al. Adverse effects of recreational and medical cannabis. Psychopharmacol Bull 2021;51:94-109. PMID: 33897066"},{"key":"ref61","unstructured":"62. Mesinga TjT, de Vries I, Kruidenier M, et al. A double-blind, randomized, placebo-controlled, cross-over study on the pharmacokinetics and effects of cannabis. Rijks\u00acinstituut voor Volksgezondheid en Milieu RIVM 2006. Available at: http:\/\/hdl.handle.net\/10029\/7272"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"63. Asbridge M, Hayden JA, Cartwright JL. Acute canna\u00acbis consumption and motor vehicle collision risk: sys-tematic review of observational studies and meta-analysis. BMJ 2012;344:e536.","DOI":"10.1136\/bmj.e536"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/dta.1393","article-title":"Alcohol and drugs in seriously injured drivers in six European countries","volume":"5","author":"Legrand","year":"2013","unstructured":"64. Legrand SA, Isalberti C, der Linden TV, et al. Alcohol and drugs in seriously injured drivers in six European countries. Drug Test Anal 2013;5:156-65.","journal-title":"Drug Test Anal"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"65. Aryana A, Williams MA. Marijuana as a trigger of cardiovascular events: speculation or scientific cer\u00actainty? Int J Cardiol 2007;118:141-4.","DOI":"10.1016\/j.ijcard.2006.08.001"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.amjcard.2013.09.042","article-title":"Adverse cardiovas-cular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know","volume":"113","author":"Thomas","year":"2014","unstructured":"66. Thomas G, Kloner RA, Rezkalla S. Adverse cardiovas-cular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol 2014;113:187-90.","journal-title":"Am J Cardiol"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"67. Jouanjus E, Lapeyre-Mestre M, Micallef J. Cannabis use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc 2014;3:e000638.","DOI":"10.1161\/JAHA.113.000638"},{"key":"ref67","unstructured":"68. deShazo RD, Parker SB, Williams D, et al. Marijua\u00acna's effects on brain structure and function: what do"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.amjmed.2018.09.006","article-title":"we know and what should we do? A brief review and commentary","volume":"132","author":"69","year":"2019","unstructured":"69. we know and what should we do? A brief review and commentary. Am J Med 2019;132:281-5.","journal-title":"Am J Med"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.coms.2018.06.001","article-title":"Epidemiology and demographics of the head and neck cancer popula\u00action","volume":"30","author":"Cohen","year":"2018","unstructured":"70. Cohen N, Fedewa S, Chen AY. Epidemiology and demographics of the head and neck cancer popula\u00action. Oral Maxillofac Surg Clin North Am 2018;30: 381-95.","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0304-3835(79)80088-9","article-title":"Mutagenic activity of marihuana smoke condensates","volume":"6","author":"Busch","year":"1979","unstructured":"71. Busch FW, Seid DA, Wei ET. Mutagenic activity of marihuana smoke condensates. Cancer Lett 1979;6: 319-24.","journal-title":"Cancer Lett"},{"key":"ref71","unstructured":"72. Aston E. NCT04269993: impact of acute cannabis administration on pain symptomology and inflam-matory markers among patients with rheumatoid or psoriatic arthritis. ClinicalTrials.gov. Published Feb\u00acruary 17, 2020. Available at: https:\/\/clinicaltrials. gov\/ct2\/show\/NCT04269993)."},{"key":"ref72","unstructured":"73. Sylvain M. NCT04402554: survey of cannabis use in patients with chronic inflammatory arthritis (Canna\u00acbisRIC). ClinicalTrials.gov. Last update posted June 2, 2021. Available at: https:\/\/clinicaltrials.gov\/ct2\/ show\/NCT04402554"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"74. Wang B, Kovalchuk A, Li D, et al. In search of pre-ventative strategies: novel high-CBD cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues. Aging (Albany NY) 2020;12:22425-44.","DOI":"10.18632\/aging.202225"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388:2023-38.","journal-title":"Lancet"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.autrev.2017.09.013","article-title":"Imaging aspects of interstitial lung disease in patients with rheumatoid arthritis: literature review","volume":"17","author":"Balbir-Gurman","year":"2018","unstructured":"75. Balbir-Gurman A, Guralnik L, Yigla M, Braun-Moscovici Y, Hardak E. Imaging aspects of interstitial lung disease in patients with rheumatoid arthritis: literature review. Autoimmun Rev 2018;17:87-93.","journal-title":"Autoimmun Rev"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","article-title":"The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study","volume":"73","author":"Cross","year":"2014","unstructured":"76. Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014;73: 1316-22.","journal-title":"Ann Rheum Dis"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s10067-020-05438-0","article-title":"Chronological effects of non-steroidal anti-inflammatory drug therapy on oxidative stress and antioxidant status in patients with rheumatoid arthritis","volume":"40","author":"Nawaz","year":"2021","unstructured":"77. Nawaz H, Ali A, Rehman T, Aslam A. Chronological effects of non-steroidal anti-inflammatory drug therapy on oxidative stress and antioxidant status in patients with rheumatoid arthritis. Clin Rheumatol 2021;40:1767-78.","journal-title":"Clin Rheumatol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","unstructured":"78. Smolen JS, Landew\u00e9 R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.","journal-title":"Ann Rheum Dis"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","unstructured":"79. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:1-25.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJM199507203330302","article-title":"The effect of glucocorticoids on joint destruction in rheumatoid arthritis","volume":"333","author":"Kirwan","year":"1995","unstructured":"80. Kirwan JR; Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.","journal-title":"N Engl J Med"},{"key":"ref81","unstructured":"81. Yasir M, Goyal A, Sonthalia S. Corticosteroid Adverse Effects. 2023 Jul 3. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2023 Jan. PMID: 30285357. Available at: https:\/\/www.ncbi. nlm.nih.gov\/books\/NBK531462\/ (accessed October 5, 2023)."},{"key":"ref82","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/17425255.2020.1777279","article-title":"Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients","volume":"16","author":"Szostak","year":"2020","unstructured":"82. Szostak B, Machaj F, Rosik J, Pawlik A. Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients. Expert Opin Drug Metab Toxicol 2020;16:617-26.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","unstructured":"83. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73:529-35.","journal-title":"Ann Rheum Dis"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"84. Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it's been... Headache 2015;55:885-916.","DOI":"10.1111\/head.12570"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"85. Gould J. The cannabis crop. Nature 2015;525:S2-3.","DOI":"10.1038\/525S2a"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fpls.2016.00019","article-title":"Cannabis sativa: the plant of the thousand and one molecules","volume":"7","author":"Andre","year":"2016","unstructured":"86. Andre CM, Hausman JF, Guerriero G. Cannabis sativa: the plant of the thousand and one molecules. Front Plant Sci 2016;7:19.","journal-title":"Front Plant Sci"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"87. Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 2008;Suppl 1:10-14.","DOI":"10.1111\/j.1365-2826.2008.01671.x"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"88. Smith TH, Sim-Selley LJ, Selley DE. Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol 2010;160:454-66.","DOI":"10.1111\/j.1476-5381.2010.00777.x"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3389\/fimmu.2021.631233","article-title":"The immunopathology of COVID-19 and the cannabis paradigm","volume":"12","author":"Paland","year":"2021","unstructured":"89. Paland N, Pechkovsky A, Aswad M, et al. The immunopathology of COVID-19 and the cannabis paradigm. Front Immunol 2021;12:327.","journal-title":"Front Immunol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature08144","article-title":"The structure and function of G-protein-coupled receptors","volume":"459","author":"Rosenbaum","year":"2009","unstructured":"90. Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature 2009;459:356-63.","journal-title":"Nature"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"91. Marsicano G, Kuner R. Anatomical Distribution of Receptors, Ligands and Enzymes in the Brain and in the Spinal Cord: Circuitries and Neurochemistry. In: K\u00f6falvi A, ed. Cannabinoids and the Brain. New York, NY: Springer; 2008:161-201.","DOI":"10.1007\/978-0-387-74349-3_10"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1073\/pnas.96.10.5780","article-title":"Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice","volume":"96","author":"Zimmer","year":"1999","unstructured":"92. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 1999;96:5780-5.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00213-017-4537-5","article-title":"Regulation of cannabinoid CB2 receptor constitutive activity in vivo: repeated treatments with inverse agonists reverse the acute activation of JNK and associated apoptotic signaling in mouse brain","volume":"234","author":"Salort","year":"2017","unstructured":"93. Salort G, \u00c1lvaro-Bartolom\u00e9 M, Garc\u00eda-Sevilla JA. Regulation of cannabinoid CB2 receptor constitutive activity in vivo: repeated treatments with inverse agonists reverse the acute activation of JNK and associated apoptotic signaling in mouse brain. Psychopharmacology (Berl) 2017;234:925-41.","journal-title":"Psychopharmacology (Berl)"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","unstructured":"94. Palazuelos J, Aguado T, Pazos MR, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009;132: 3152-64.","journal-title":"Brain"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0009-3084(00)00195-X","article-title":"Cannabinoid receptors and the regulation of immune response","volume":"108","author":"Berdyshev","year":"2000","unstructured":"95. Berdyshev EV. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 2000; 108:169-90.","journal-title":"Chem Phys Lipids"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1021\/jm050709m","article-title":"New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity","volume":"49","author":"Ben-Shabat","year":"2006","unstructured":"96. Ben-Shabat S, Hanu\u0161 LO, Katzavian G, Gallily R. New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. J Med Chem 2006;49:1113-17.","journal-title":"J Med Chem"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"875546","DOI":"10.3389\/fimmu.2022.875546","article-title":"High-CBD extract (CBD-X) downregulates cytokine storm systemically and locally in inflamed lungs","volume":"13","author":"Aswad","year":"2022","unstructured":"97. Aswad M, Hamza H, Pechkovsky A, et al. High-CBD extract (CBD-X) downregulates cytokine storm systemically and locally in inflamed lungs. Front Immunol 2022;13:875546.","journal-title":"Front Immunol"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"6461","DOI":"10.4049\/jimmunol.164.12.6461","article-title":"9-Tetrahydrocannabinol treatment suppresses immunity and early IFN-, IL-12, and IL-12 receptor 2 responses to Legionella pneumophila infection 1","volume":"164","author":"Klein","year":"2000","unstructured":"98. Klein TW, Newton CA, Nakachi N, Friedman H. 9-Tetrahydrocannabinol treatment suppresses immunity and early IFN-, IL-12, and IL-12 receptor 2 responses to Legionella pneumophila infection 1. J Immunol 2000;164:6461-6.","journal-title":"J Immunol"},{"key":"ref99","unstructured":"99. Jeon YJ, Yang KH, Pulaski JT, Kaminski NE. Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B\/Rel activation. Mol Pharmacol 1996;50:334-41. PMID: 8700141"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.3390\/ijms20071673","article-title":"Future aspects for cannabinoids in breast cancer therapy","volume":"20","author":"Kiskov\u00e1","year":"2019","unstructured":"100. Kiskov\u00e1 T, Mungenast F, Suv\u00e1kov\u00e1 M, J\u00e4ger W, Thalhammer T. Future aspects for cannabinoids in breast cancer therapy. Int J Mol Sci 2019;20:1673.","journal-title":"Int J Mol Sci"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1074\/jbc.M109.069294","article-title":"Cannabinoids \u03949-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-\u03baappaB and interferon-\u03b2\/STAT proinflammatory pathways in BV-2 microglial cells","volume":"285","author":"Kozela","year":"2010","unstructured":"101. Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z. Cannabinoids \u03949-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-\u03baappaB and interferon-\u03b2\/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem 2010;285:1616-26.","journal-title":"J Biol Chem"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"102. Juknat A, Gao F, Coppola G, Vogel Z, Kozela E. miRNA expression profiles and molecular networks in resting and LPS-activated BV-2 microglia-effect of cannabinoids. PLoS One 2019;14:e0212039.","DOI":"10.1371\/journal.pone.0212039"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1211\/jpp.58.3.0009","article-title":"Arthritis and cannabinoids: HU-210 and Win-55,212-2 prevent IL-1 \u03b1-induced matrix degradation in bovine articular chondrocytes in-vitro","volume":"58","author":"Mbvundula","year":"2010","unstructured":"103. Mbvundula EC, Bunning RAD, Rainsford KD. Arthritis and cannabinoids: HU-210 and Win-55,212-2 prevent IL-1 \u03b1-induced matrix degradation in bovine articular chondrocytes in-vitro. J Pharm Pharmacol 2010;58:351-8.","journal-title":"J Pharm Pharmacol"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.bcp.2004.11.018","article-title":"Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage","volume":"69","author":"Mbvundula","year":"2005","unstructured":"104. Mbvundula EC, Bunning RAD, Rainsford KD. Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. Biochem Pharmacol 2005;69:635-40.","journal-title":"Biochem Pharmacol"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/1529-0131(199801)41:1<163::AID-ART20>3.0.CO;2-9","article-title":"Dimethylheptyl-THC-11 OIC acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure","volume":"41","author":"Zurier","year":"1998","unstructured":"105. Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SA, Burstein SH. Dimethylheptyl-THC-11 OIC acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum 1998;41:163-70.","journal-title":"Arthritis Rheum"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"113693","DOI":"10.1016\/j.bcp.2019.113693","article-title":"Tetrahydrocannabinolic acid A (THCA-A) reduces adiposity and prevents metabolic disease caused by diet-induced obesity","volume":"171","author":"Palomares","year":"2020","unstructured":"106. Palomares B, Ruiz-Pino F, Garrido-Rodriguez M, et al. Tetrahydrocannabinolic acid A (THCA-A) reduces adiposity and prevents metabolic disease caused by diet-induced obesity. Biochem Pharmacol 2020;171: 113693.","journal-title":"Biochem Pharmacol"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0091-3057(97)00583-2","article-title":"Characterization of \u03949-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats","volume":"60","author":"Smith","year":"1998","unstructured":"107. Smith FL, Fujimori K, Lowe J, Welch SP. Characterization of \u03949-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav 1998;60:183-91.","journal-title":"Pharmacol Biochem Behav"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"9561","DOI":"10.1073\/pnas.160105897","article-title":"The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis","volume":"97","author":"Malfait","year":"2000","unstructured":"108. Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 2000;97: 9561-6.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejphar.2007.05.024","article-title":"The antinociceptive effect of \u03949-tetrahydrocannabinol in the arthritic rat involves the CB2 cannabinoid receptor","volume":"570","author":"Cox","year":"2007","unstructured":"109. Cox ML, Haller VL, Welch SP. The antinociceptive effect of \u03949-tetrahydrocannabinol in the arthritic rat involves the CB2 cannabinoid receptor. Eur J Pharmacol 2007;570:50-6.","journal-title":"Eur J Pharmacol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/art.20050","article-title":"A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis","volume":"50","author":"Sumariwalla","year":"2004","unstructured":"110. Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 2004;50:985-98.","journal-title":"Arthritis Rheum"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejp.818","article-title":"Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis","volume":"20","author":"Hammell","year":"2016","unstructured":"111. Hammell DC, Zhang LP, Ma F, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain 2016;20:936-48.","journal-title":"Eur J Pain"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"112. Richardson D, Pearson RG, Kurian N, et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 2008; 10:R43.","DOI":"10.1186\/ar2401"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"IB","year":"2007","unstructured":"113. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7: 429-42.","journal-title":"Nat Rev Immunol"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/ar2304","article-title":"Proteinases in the joint: clinical relevance of proteinases in joint destruction","volume":"9","author":"Rengel","year":"2007","unstructured":"114. Rengel Y, Ospelt C, Gay S. Proteinases in the joint: clinical relevance of proteinases in joint destruction. Arthritis Res Ther 2007;9:221.","journal-title":"Arthritis Res Ther"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/jcb.21046","article-title":"Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid","volume":"100","author":"Johnson","year":"2007","unstructured":"115. Johnson DR, Stebulis JA, Rossetti RG, Burstein SH, Zurier RB. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. J Cell Biochem 2007;100:184-90.","journal-title":"J Cell Biochem"},{"key":"ref116","unstructured":"116. Selvi E, Lorenzini S, Garcia-Gonzalez E, et al. Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. Clin Exp Rheumatol 2008;26:574-81. PMID: 18799087."},{"key":"ref117","doi-asserted-by":"publisher","unstructured":"117. Lowin T, Pongratz G, Straub RH. The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targets. J Inflamm (Lond) 2016:13:15.","DOI":"10.1186\/s12950-016-0114-7"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41419-020-02892-1","article-title":"Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts","volume":"11","author":"Lowin","year":"2020","unstructured":"118. Lowin T, Tingting R, Zurmahr J, Classen T, Schneider M, Pongratz G. Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts. Cell Death Dis 2020;11:714.","journal-title":"Cell Death Dis"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1097\/j.pain.0000000000001896","article-title":"A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain","volume":"161","author":"Verrico","year":"2020","unstructured":"119. Verrico CD, Wesson S, Konduri V, et al. A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain 2020;161:2191-202.","journal-title":"Pain"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41423-020-0437-4","article-title":"Cannabinoids drive Th17 cell differentiation in patients with rheumatic autoimmune diseases","volume":"18","author":"Kotschenreuther","year":"2021","unstructured":"120. Kotschenreuther K, Waqu\u00e9 I, Yan S, et al. Cannabinoids drive Th17 cell differentiation in patients with rheumatic autoimmune diseases. Cell Mol Immunol 2021;18:764-6.","journal-title":"Cell Mol Immunol"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1365-2044.2004.03674.x","article-title":"Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 \"N of 1\" studies","volume":"59","author":"Notcutt","year":"2004","unstructured":"121. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 \"N of 1\" studies. Anaesthesia 2004; 59:440-52.","journal-title":"Anaesthesia"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/kei183","article-title":"Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis","volume":"45","author":"Blake","year":"2006","unstructured":"122. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006;45:50-2.","journal-title":"Rheumatology (Oxford)"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jpain.2012.10.009","article-title":"Low-dose vaporized cannabis significanly improves neuropathic pain","volume":"14","author":"Wilsey","year":"2013","unstructured":"123. Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significanly improves neuropathic pain. J Pain 2013;14:136-48.","journal-title":"J Pain"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/j.pain.0000000000001464","article-title":"An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia","volume":"160","author":"Van De Donk","year":"2019","unstructured":"124. Van De Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, Van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain 2019;160:860-9.","journal-title":"Pain"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"344","DOI":"10.14740\/jocmr4210","article-title":"A scoping review on clinical trials of pain reduction with cannabis administration in adults","volume":"12","author":"Haleem","year":"2020","unstructured":"125. Haleem R, Wright R. A scoping review on clinical trials of pain reduction with cannabis administration in adults. J Clin Med Res 2020;12:344-51.","journal-title":"J Clin Med Res"},{"key":"ref126","unstructured":"126. Van den Berg M, John M, Black M, et al. Cannabis-based medicinal products in arthritis, a painful conundrum. N Z Med J 2020;133:35-45. PMID: 32438375"},{"key":"ref127","doi-asserted-by":"publisher","unstructured":"127. Weizman L, Dayan L, Brill S, et al. Cannabis analgesia in chronic neuropathic pain is associated with altered brain connectivity. Neurology 2018;91:e1285-94.","DOI":"10.1212\/WNL.0000000000006293"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1097\/j.pain.0000000000000706","article-title":"Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis","volume":"157","author":"Ste-Marie","year":"2016","unstructured":"128. Ste-Marie PA, Shir Y, Rampakakis E, et al. Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis. Pain 2016;157:2792-7.","journal-title":"Pain"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ejp.1118","article-title":"Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - an overview of systematic reviews","volume":"22","author":"H\u00e4user","year":"2018","unstructured":"129. H\u00e4user W, Petzke F, Fitzcharles MA. Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - an overview of systematic reviews. Eur J Pain 2018;22:455-70.","journal-title":"Eur J Pain"},{"key":"ref130","doi-asserted-by":"publisher","unstructured":"130. Jennings JM, Williams MA, Levy DL, Johnson RM, Eschen CL, Dennis DA. Has self-reported marijuana use changed in patients undergoing total joint arthroplasty after the legalization of marijuana? Clin Orthop Relat Res 2019;477:95-100.","DOI":"10.1097\/CORR.0000000000000339"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1742-1241.2004.00271.x","article-title":"The medicinal use of cannabis in the UK: results of a nationwide survey","volume":"59","author":"Ware","year":"2005","unstructured":"131. Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract 2005;59:291-5.","journal-title":"Int J Clin Pract"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/rheumatology\/keaa534","article-title":"Cannabis use assessment and its impact on pain in rheumatologic diseases: a systematic review and meta-analysis","volume":"60","author":"Guillouard","year":"2021","unstructured":"132. Guillouard M, Authier N, Pereira B, Soubrier M, Mathieu S. Cannabis use assessment and its impact on pain in rheumatologic diseases: a systematic review and meta-analysis. Rheumatology (Oxford) 2021;60:549-56.","journal-title":"Rheumatology (Oxford)"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/acr2.11138","article-title":"Medical cannabis use by rheumatology patients following recreational legalization: a prospective observational study of 1000 patients in Canada","volume":"2","author":"Fitzcharles","year":"2020","unstructured":"133. Fitzcharles MA, Rampakakis E, Sampalis J, et al. Medical cannabis use by rheumatology patients following recreational legalization: a prospective observational study of 1000 patients in Canada. ACR Open Rheumatol 2020;2:286-93.","journal-title":"ACR Open Rheumatol"},{"key":"ref134","unstructured":"134. Urits I, Charipova K, Gress K, et al. Adverse effects of recreational and medical cannabis. Psychopharmacol Bull 2021;51:94-109. PMID: 33897066"},{"key":"ref135","unstructured":"135. Mesinga TjT, de Vries I, Kruidenier M, et al. A double-blind, randomized, placebo-controlled, cross-over study on the pharmacokinetics and effects of cannabis. Rijksinstituut voor Volksgezondheid en Milieu RIVM 2006. Available at: http:\/\/hdl.handle.net\/10029\/7272"},{"key":"ref136","doi-asserted-by":"publisher","unstructured":"136. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012;344:e536.","DOI":"10.1136\/bmj.e536"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/dta.1393","article-title":"Alcohol and drugs in seriously injured drivers in six European countries","volume":"5","author":"Legrand","year":"2013","unstructured":"137. Legrand SA, Isalberti C, der Linden TV, et al. Alcohol and drugs in seriously injured drivers in six European countries. Drug Test Anal 2013;5:156-65.","journal-title":"Drug Test Anal"},{"key":"ref138","doi-asserted-by":"publisher","unstructured":"138. Aryana A, Williams MA. Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? Int J Cardiol 2007;118:141-4.","DOI":"10.1016\/j.ijcard.2006.08.001"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.amjcard.2013.09.042","article-title":"Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know","volume":"113","author":"Thomas","year":"2014","unstructured":"139. Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol 2014;113:187-90.","journal-title":"Am J Cardiol"},{"key":"ref140","doi-asserted-by":"publisher","unstructured":"140. Jouanjus E, Lapeyre-Mestre M, Micallef J. Cannabis use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc 2014;3:e000638.","DOI":"10.1161\/JAHA.113.000638"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.amjmed.2018.09.006","article-title":"Marijuana's effects on brain structure and function: what do we know and what should we do? A brief review and commentary","volume":"132","author":"deShazo","year":"2019","unstructured":"141. deShazo RD, Parker SB, Williams D, et al. Marijuana's effects on brain structure and function: what do we know and what should we do? A brief review and commentary. Am J Med 2019;132:281-5.","journal-title":"Am J Med"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.coms.2018.06.001","article-title":"Epidemiology and demographics of the head and neck cancer population","volume":"30","author":"Cohen","year":"2018","unstructured":"142. Cohen N, Fedewa S, Chen AY. Epidemiology and demographics of the head and neck cancer population. Oral Maxillofac Surg Clin North Am 2018;30: 381-95.","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0304-3835(79)80088-9","article-title":"Mutagenic activity of marihuana smoke condensates","volume":"6","author":"Busch","year":"1979","unstructured":"143. Busch FW, Seid DA, Wei ET. Mutagenic activity of marihuana smoke condensates. Cancer Lett 1979;6: 319-24.","journal-title":"Cancer Lett"},{"key":"ref144","unstructured":"144. Aston E. NCT04269993: impact of acute cannabis administration on pain symptomology and inflammatory markers among patients with rheumatoid or psoriatic arthritis. ClinicalTrials.gov. Published February 17, 2020. Available at: https:\/\/clinicaltrials. gov\/ct2\/show\/NCT04269993)."},{"key":"ref145","unstructured":"145. Sylvain M. NCT04402554: survey of cannabis use in patients with chronic inflammatory arthritis (CannabisRIC). ClinicalTrials.gov. Last update posted June 2, 2021. Available at: https:\/\/clinicaltrials.gov\/ct2\/ show\/NCT04402554"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"22425","DOI":"10.18632\/aging.202225","article-title":"In search of preventative strategies: novel high-CBD cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues","volume":"12","author":"Wang","year":"2020","unstructured":"146. Wang B, Kovalchuk A, Li D, et al. In search of preventative strategies: novel high-CBD cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues. Aging (Albany NY) 2020;12:22425-44.","journal-title":"Aging (Albany NY)"}],"container-title":["Rambam Maimonides Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.rmmj.org.il\/userimages\/1676\/1\/PublishFiles\/1731Article.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T11:16:47Z","timestamp":1728904607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.rmmj.org.il\/issues\/60\/articles\/1731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":147,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,10,30]]}},"URL":"https:\/\/doi.org\/10.5041\/rmmj.10509","relation":{},"ISSN":["2076-9172"],"issn-type":[{"value":"2076-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]}}}